GW 181771

Drug Profile

GW 181771

Alternative Names: GI 181771; GSKI-181771X; GW-181771

Latest Information Update: 20 Apr 2011

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Obesity therapies
  • Mechanism of Action Cholecystokinin A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bulimia nervosa
  • Discontinued Obesity

Most Recent Events

  • 21 Apr 2005 Discontinued - Phase-II for Obesity in United Kingdom (unspecified route)
  • 14 Nov 2002 Phase-II clinical trials in Obesity in United Kingdom (unspecified route)
  • 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top